Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 47

1.

Position paper of the Italian Association of Medical Oncology on early palliative care in oncology practice (Simultaneous Care).

Zagonel V, Franciosi V, Brunello A, Biasco G, Broglia C, Cattaneo D, Cavanna L, Corsi D, Farina G, Fioretto L, Gamucci T, Lanzetta G, Magarotto R, Maltoni M, Marchetti P, Massa E, Mastromauro C, Melotti B, Meriggi F, Nacci A, Pavese I, Piva E, Quirino M, Roselli M, Sacco C, Tonini G, Trentin L, Ucci G, Labianca R, Gori S, Pinto C, Cascinu S; AIOM Simultaneous and Continuous Care (SCC), Task Force: ESMO Italian DCs.

Tumori. 2017 Jan 21;103(1):9-14. doi: 10.5301/tj.5000593. Epub 2016 Dec 19. Review.

PMID:
28009422
2.

Early Integration of Palliative Care in Oncology Practice: Results of the Italian Association of Medical Oncology (AIOM) Survey.

Zagonel V, Torta R, Franciosi V, Brunello A, Biasco G, Cattaneo D, Cavanna L, Corsi D, Farina G, Fioretto L, Gamucci T, Lanzetta G, Magarotto R, Maltoni M, Mastromauro C, Melotti B, Meriggi F, Pavese I, Piva E, Sacco C, Tonini G, Trentin L, Ermacora P, Varetto A, Merlin F, Gori S, Cascinu S, Pinto C; AIOM Simultaneous & Continuous Care (SCC) Task Force-ESMO-DCs.

J Cancer. 2016 Sep 27;7(14):1968-1978. eCollection 2016.

3.

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.

Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Láng I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thürlimann B; BIG 1-98 Collaborative Group; International Breast Cancer Study Group (IBCSG).

Lancet Oncol. 2011 Nov;12(12):1101-8. doi: 10.1016/S1470-2045(11)70270-4. Epub 2011 Oct 20.

4.

The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.

Chirgwin J, Sun Z, Smith I, Price KN, Thürlimann B, Ejlertsen B, Bonnefoi H, Regan MM, Goldhirsch A, Coates AS; BIG 1-98 Collaborative and International Breast Cancer Study Groups.

Breast Cancer Res Treat. 2012 Jan;131(1):295-306. doi: 10.1007/s10549-011-1741-6. Epub 2011 Sep 4.

5.

Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.

Musolino A, Boggiani D, Panebianco M, Vasini G, Salvagni S, Franciosi V, Ardizzoni A.

Cancer. 2011 Mar 1;117(5):964-73. doi: 10.1002/cncr.25582. Epub 2010 Oct 19.

6.

The medical oncologist's role in palliative care: AIOM's position.

Zagonel V, Cavanna L, Cetto G, Ciaparrone M, Di Rocco C, Franciosi V, Maltoni M, Marchetti P, Martoni A, Mastromauro C, Mazzoli M, Moro C, Pinto C, Porzio G, Trentin L, Boccardo F; Task Force AIOM Palliative Care in Oncology.

Tumori. 2009 Nov-Dec;95(6):652-4. No abstract available.

7.

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.

BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Forbes J, Price KN, Regan MM, Gelber RD, Coates AS.

N Engl J Med. 2009 Aug 20;361(8):766-76. doi: 10.1056/NEJMoa0810818.

8.

Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer.

Giobbie-Hurder A, Price KN, Gelber RD; International Breast Cancer Study Group; BIG 1-98 Collaborative Group.

Clin Trials. 2009 Jun;6(3):272-87. doi: 10.1177/1740774509105380.

9.

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.

Rabaglio M, Sun Z, Price KN, Castiglione-Gertsch M, Hawle H, Thürlimann B, Mouridsen H, Campone M, Forbes JF, Paridaens RJ, Colleoni M, Pienkowski T, Nogaret JM, Láng I, Smith I, Gelber RD, Goldhirsch A, Coates AS; BIG 1-98 Collaborative and International Breast Cancer Study Groups.

Ann Oncol. 2009 Sep;20(9):1489-98. doi: 10.1093/annonc/mdp033. Epub 2009 May 27.

10.

Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers.

Tiseo M, Rossi G, Capelletti M, Sartori G, Spiritelli E, Marchioni A, Bozzetti C, De Palma G, Lagrasta C, Campanini N, Camisa R, Boni L, Franciosi V, Rindi G, Ardizzoni A.

Lung Cancer. 2010 Mar;67(3):355-60. doi: 10.1016/j.lungcan.2009.04.021. Epub 2009 May 26.

PMID:
19473722
11.

Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.

Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, Maiorano E, MacGrogan G, Braye SG, Ohlschlegel C, Neven P, Orosz Z, Olszewski WP, Knox F, Thürlimann B, Price KN, Castiglione-Gertsch M, Gelber RD, Gusterson BA, Goldhirsch A; Breast International Group Trial 1-98.

J Clin Oncol. 2008 Dec 1;26(34):5569-75. doi: 10.1200/JCO.2008.17.0829. Epub 2008 Nov 3.

12.

Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer.

Tiseo M, Capelletti M, De Palma G, Franciosi V, Cavazzoni A, Mozzoni P, Alfieri RR, Goldoni M, Galetti M, Bortesi B, Bozzetti C, Loprevite M, Boni L, Camisa R, Rindi G, Petronini PG, Ardizzoni A.

J Thorac Oncol. 2008 Oct;3(10):1104-11. doi: 10.1097/JTO.0b013e3181861d67.

13.

Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon alpha-2a as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomised multicentre trial.

Chiesa MD, Passalacqua R, Michiara M, Franciosi V, Di Costanzo F, Bisagni G, Camisa R, Buti S, Tomasello G, Cocconi G; Italian Oncology Group for Clinical Research.

Acta Biomed. 2007 Dec;78(3):204-9.

PMID:
18330080
14.

Comparison between epidermal growth factor receptor (EGFR) gene expression in primary non-small cell lung cancer (NSCLC) and in fine-needle aspirates from distant metastatic sites.

Bozzetti C, Tiseo M, Lagrasta C, Nizzoli R, Guazzi A, Leonardi F, Gasparro D, Spiritelli E, Rusca M, Carbognani P, Majori M, Franciosi V, Rindi G, Ardizzoni A.

J Thorac Oncol. 2008 Jan;3(1):18-22. doi: 10.1097/JTO.0b013e31815e8ba2.

15.

Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancer.

Loprevite M, Tiseo M, Chiaramondia M, Capelletti M, Bozzetti C, Bortesi B, Naldi N, Nizzoli R, Dadati P, Kunkl A, Zennaro D, Lagrasta C, Campanini N, Spiritelli E, Camisa R, Grossi F, Rindi G, Franciosi V, Ardizzoni A.

Clin Cancer Res. 2007 Nov 1;13(21):6518-26.

16.

[Influence of admission glucose level on long-term prognosis in patients with acute coronary syndrome].

Macín SM, Perna ER, Coronel ML, Kriskovich JO, Bayol PA, Franciosi VA, Riera-Stival JL, González-Arjol B, Badaracco JR.

Rev Esp Cardiol. 2006 Dec;59(12):1268-75. Spanish.

17.

Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancer.

Scartozzi M, Falcone A, Pucci F, Braconi C, Pierantoni C, Cavanna L, Franciosi V, Berardi R, Beretta G, Masi G, Allegrini G, Zaniboni A, Labianca R, Cascinu S.

Tumori. 2006 Sep-Oct;92(5):384-8.

PMID:
17168429
18.

Importance of early combined N-terminal pro-brain natriuretic peptide and cardiac troponin T measurements for long-term risk stratification of patients with decompensated heart failure.

Perna ER, Macin SM, Cimbaro Canella JP, Szyszko A, Franciosi V, Vargas Morales W, Bayol AP, Kriskovich JO, Medina F, Gonzalez Arjol B, Brizuela M.

J Heart Lung Transplant. 2006 Oct;25(10):1230-40.

PMID:
17045936
19.

Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients.

Scartozzi M, Franciosi V, Campanini N, Benedetti G, Barbieri F, Rossi G, Berardi R, Camisa R, Silva RR, Santinelli A, Ardizzoni A, Crinò L, Rindi G, Cascinu S.

Lung Cancer. 2006 Jul;53(1):103-9. Epub 2006 May 23.

PMID:
16716446
20.

Multi-target inhibitors in non-small cell lung cancer (NSCLC).

Tiseo M, Franciosi V, Ardizzoni A.

Ann Oncol. 2006 Mar;17 Suppl 2:ii55-57. Review. No abstract available.

PMID:
16608985

Supplemental Content

Loading ...
Support Center